CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine

Peng Xu; Jie Yao; Jin He; Long Zhao; Xiaodong Wang; Zhennan Li; Jianjun Qian

doi:10.18632/oncotarget.7447

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine

Peng Xu _, Jie Yao, Jin He, Long Zhao, Xiaodong Wang, Zhennan Li and Jianjun Qian

PDF | HTML | How to cite

Oncotarget. 2016; 7:14831-14840. https://doi.org/10.18632/oncotarget.7447

Metrics: PDF 1475 views | HTML 1818 views | ?

Abstract

Peng Xu1,*, Jie Yao1,*, Jin He1, Long Zhao1, Xiaodong Wang1, Zhennan Li1, Jianjun Qian1

1Department of Hepatobiliary and Pancreatic Surgery, Northern Jiangsu People’s Hospital, Clinical medical college of Yangzhou University, Yangzhou city, Jiangsu Provence of P. R. China, 225001

*These authors have contributed equally to this work

Correspondence to:

Jie Yao, e-mail: [email protected]

Keywords: CIP2A, pancreatic ductal adenocarcinoma, gemcitabine, prognosis, overall survival

Received: November 03, 2015 Accepted: January 29, 2016 Published: February 17, 2016

ABSTRACT

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein which participates in inhibiting tumor apoptosis in pancreatic cancer cells. Using immunohistochemical staining, we investigated the expression of CIP2A protein in 72 cases of human pancreatic ductal adenocarcinoma (PDAC) tissue and 27 cases of adjacent normal pancreatic tissue. The positive rate of CIP2A protein expression in pancreatic cancer tissue was70.83 %, which was significantly higher than that in adjacent non- cancerous pancreatic tissue (11.11%). The expression of CIP2A was found to be correlated with TNM stage, but not correlated with age, gender, tumor location, smoking status, alcohol consumption, diabetes, high blood pressure, BMI, tumor size, lymph node metastasis or distant metastases. Kaplan- Meier survival analysis showed that patients with positive CIP2A protein expression had a lower overall survival rate than patients without CIP2A expression. COX regression analysis indicated that expression of CIP2A was an independent prognostic factor for pancreatic ductal adenocarcinoma. In addition, down-regulation of CIP2A inhibited cell proliferation and increased sensitivity to gemcitabine in pancreatic cancer cells by decreasing AKT signaling pathway. Our results indicated that down-regulation of CIP2A could be a novel therapeutic strategy for pancreatic cancer

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7447

Publication Alerts

Research Papers:

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine

Abstract